Category Archives: Gene Therapy

Imagine if instead of using drugs or surgery, a doctor could simply insert a gene into a patient's cell to treat or prevent disease. Gene therapy is endeavoring to do just that and could emerge in the coming years as a viable alternative for treatment. Certain conditions that previously couldn't be treated, such as forms of blindness, types of cancer or more rare conditions like sickle cell disease are now being researched with this alternative treatment. Phil Nadeau, biotechnology analyst with Cowen and Company, predicts there will be several gene therapy products approved by the F.D.A. within the next few years. He told CNBC recently he sees more than $1 billion in gene therapy sales worldwide, which ultimately means significant investments in gene therapy in the near future. "In the past, most major companies stayed away from having gene therapy programs. In the future, we think, it's going to be a standard treatment," he said. Link: Biotech's next buzz: Gene therapy? … Continue reading →

MultiVir, a biotech developing gene therapies for cancer, filed on Monday with the SEC to raise up to $70 million in an initial public offering. The Houston, TX-based company, which was founded in 2009, plans to list on the NASDAQ under the symbol MVIR. MultiVir initially filed confidentially on December 22, 2014. RBC Capital Markets is the sole bookrunner on the deal. No pricing terms were disclosed. Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc. Original post: Cancer gene therapy biotech MultiVir files for a $70 million IPO … Continue reading →

Gentech Lesson: Gene Therapy Momes Honors Bio EB/1: Gentech Lesson on Gene Therapy. By Sarah, Jordan, Lisa, Sydney. By: Sarah Minster … Continue reading →

Colorblind monkey cured by gene therapy... Dalton, a squirrel monkey, is cured of colorblindness by gene therapy and completes color vision discrimination test. Dalton, a squirrel monkey, is cured of colorblindness by gene therapy and... By: LisaMarintMEw … Continue reading →

NEW YORK (TheStreet) -- The next investor referendum on the resurgent gene-therapy field will arrive next month whenCelladon (CLDN)is expected to announce results from a mid-stage study of a gene therapy aimed atimproving the heart's pumping ability in patients suffering fromthe organ's advanced failure. Gene therapy uses engineered viruses to replace defective, disease-causing genes. Celladon's lead therapy, Mydicar, is a virus engineered to insert a working gene capable of producing a protein called SERCA2a into heart-failure patients. SERCA2a is responsible for helping heart muscles contract and pump blood more efficiently. Heart-failure patients have low levels of SERCA2a and hearts that do a poor job pumping blood around the body. Celladon believes infusing Mydicar should lead to higher SERCA2a levels and improved heart function. Must Read: 5 Stocks Warren Buffett Is Selling Celladon went public in January 2014 at $8 per share. The stock was tradingat $24.10, down 1.8%, on Wednesday morning, after rising by more than 30% in March as investors anticipate the Mydicar study results. View original post here: Celladon Heart-Failure Study Looms Large as Next Big Test for Gene Therapy … Continue reading →

A simulation from the Neitz lab of what colorblindness looks like, with normal color vision on the left and red-green colorblindness on the right. Courtesy of Neitz Laboratory hide caption A simulation from the Neitz lab of what colorblindness looks like, with normal color vision on the left and red-green colorblindness on the right. More than 10 million Americans have trouble distinguishing red from green or blue from yellow, and there's no treatment for colorblindness. A biotech company and two scientists hope to change that. On Wednesday, Avalanche Biotechnologies in Menlo Park and the University of Washington in Seattle announced a licensing agreement to develop the first treatment for colorblindness. The deal brings together a gene therapy technique developed by Avalanche with the expertise of vision researchers at the University of Washington. "Our goal is to be treating colorblindness in clinical trials in patients in the next one to two years," says Thomas Chalberg, the founder and CEO of Avalanche. Dalton the squirrel monkey during the color vision test. Courtesy of Neitz Laboratory hide caption Dalton the squirrel monkey during the color vision test. The agreement has its roots in a scientific breakthrough that occurred six years ago. That's when … Continue reading →

Gene therapy for CCALD Description. By: bluebird bio … Continue reading →

Explaining gene therapy for wet AMD Shows how wet macular degeneration destructs vision, how secretion gene therapy works and how people can benefit. By: Elizabeth Rakoczy … Continue reading →

Lumber Liquidators Scandal with Dr Mitch Gaynor on Fox Business Subscribe to the GeneChanger YouTube: http://goo.gl/jOPcep Dr Mitch Gaynor, Medical Oncologist at Cornell Medical Center Author of "Gene Therapy Plan" on Fox Business. The Gene Therapy... By: Mitchell Gaynor M.D. … Continue reading →

Gene Therapy Respiratory Insight: Trends and Challenges Analysed in Research Report Gene Therapy Respiratory Insight: Pipeline Assessment, Market Trend, Technology and Competitive Landscape provides in depth insights into the Respiratory gene therapy. It has covered 5+... By: James Jacob … Continue reading →